177Lu-DOTAGA.FAPi

N/A

Report date: 2025/11/18 13:22:59
NME

Base Information

Drug Name177Lu-DOTAGA.FAPi
Drug Alias Name[177Lu]-DOTAGA.FAPiDOTAGA.FAPi-177-lutetiumfibroblast activation protein targeting DOTAGA dimer radionuclide therapy (All India Institute of Medical Sciences/Johannes Gutenberg University of Mainz)lutetium-177-DOTAGA.FAPiDOTAGA.FAPi-177Lu +[10] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentSmall moleculesRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4] 
Mechanisms of ActionFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Metastatic breast cancerUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaGermanyIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJohannes Gutenberg University Of Mainz
China Registration ClassN/A

Develop Information

Active CompaniesAll India Institute Of Medical Sciences, New DelhiJohannes Gutenberg University Of MainzTelix Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Metastatic breast cancerUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A